Literature DB >> 3902212

Athymic mouse model of a human T-cell tumor.

R O Dillman, D E Johnson, D L Shawler, S E Halpern, J E Leonard, P L Hagan.   

Abstract

Because of the large number of different immunoconjugates which can be produced from monoclonal antibody-directed anti-cancer therapy, it would be useful to have in vivo tumor models to compare such preparations. Although historically human leukemias-lymphomas have been difficult to establish in athymic mice we have succeeded in establishing human T-cell tumors from primary MOLT-4 cultures in 290 of 353 animals and have successfully transferred tumors in 42 of 45 animals during ten serial passages. The potential utility of this model for testing immunoconjugates of murine monoclonal antibody T101 have been confirmed by: (a) in all 148 tumors sampled including all passaged tumors the human T-cell antigen, T65, was expressed in a manner identical to that of cultured cells; (b) 111In-T101 was concentrated preferentially in the tumor; and (c) T101 injected by both the i.p. and i.v. routes bound to tumor and induced antigenic modulation to the same extent as that observed previously in vitro and in human studies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3902212

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.

Authors:  H Hara; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

2.  Immunotoxin studies in a model of human T-cell acute lymphoblastic leukemia developed in severe combined immune-deficient mice.

Authors:  B J Morland; D Boehm; S U Flavell; J A Kohler; D J Flavell
Journal:  Cell Biophys       Date:  1994

3.  Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.

Authors:  B J Morland; J Barley; D Boehm; S U Flavell; N Ghaleb; J A Kohler; K Okayama; B Wilkins; D J Flavell
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.